Lincbiotech is a joint initiative of the Laboratorios de Investigación en Neurociencias Clínicas (LINC), the Fundación del Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS) and a Galician business group with extensive experience in the field of technological business. It develops innovative tools for the diagnosis and treatment of highly prevalent neurological diseases. The company leverages advanced neuroimaging processing, in vitro assays and artificial intelligence techniques to facilitate diagnosis.

Lincbiotech is focused on two lines of research: one oriented towards diagnostics, such as the Minerva Stroke and Minerva Spine solutions, and the other towards the development of therapies, such as Aptadegrad, a flexible platform developed for the discovery of new compounds to reduce costs and overcome logistical limitations in the research of new drugs. 
 
Accurate diagnosis with Minerva 
One of Lincbiotech's main contributions is Minerva Stroke, an innovative clinical decision support system designed to improve the management of stroke patients. Based on artificial intelligence algorithms and advanced brain image processing, Minerva Stroke provides fast and accurate information on computed tomography (popularly known as "tac") and magnetic resonance imaging, facilitating early diagnosis and more effective intervention. 

With a seamless workflow and easy-to-use cloud-based software, Minerva Stroke delivers comprehensive reports within minutes, enabling optimal clinical management of stroke patients.

The second software application that Lincbiotech has developed is marketed under the brand name Minerva Spine. In this case, the advanced spine image analysis application aids medical diagnosis by providing accurate and intuitive biomarker findings. From spinal MRI scans, Minerva Spine automatically provides reports with key pathological findings. 

Advances for Alzheimer's patients
Alzheimer's disease (AD) is an irreversible and progressive brain disorder that slowly destroys memory and the ability to think and, over time, the ability to perform the simplest tasks. According to a report by Alzheimer's Disease International, more than 46 million people are currently living with dementia worldwide, which is more than the total population of Spain.
With a focus on early diagnosis, Lincbiotech launched the ELISA kit, the first product in this field to diagnose Alzheimer's even in its earliest stages, which can have a significant impact on the development and quality of life of patients.

Aptadegrad
Lincbiotech is leading a project funded by the European Innovation Council from 2022 to develop molecules (protein degraders) that slow down serious diseases. The Neuroaging Group of the Instituto de Investigación Sanitaria de Santiago (IDIS) and four other entities from Belgium, Portugal and the United Kingdom are also participating in this project. 

The EIC Pathfinder Open call, one of the most competitive in the European Union, finances projects that propose the application of state-of-the-art technology for the development of innovative solutions to the major challenges facing European society in areas such as health, energy and the environment. Of the 858 projects submitted, only 57 were selected, 7% of the total. This was the first time that the EIC grant went to a biotech company based in Galicia.

Aptadegrad is a selective protein degradation platform that offers a new approach to neurodegenerative diseases. Thanks to its flexibility and cost-reducing efficacy, Aptadegrad presents itself as a promising tool in the fight against neurological diseases.